U.S. Banks Stock News

Dorman Products (NasdaqGS:DORM) has appointed President and CEO Kevin Olsen as Chairman of the Board. Former Chairman Steven Berman will remain on the board following this leadership change. The move combines the CEO and Chairman roles, signaling a new governance structure for the company. Dorman Products, which focuses on replacement parts for the automotive aftermarket, now has Kevin Olsen serving as President, CEO and Chairman. For investors, this kind of leadership consolidation can...

Giftify’s CardCash will be integrated into Capital One Shopping, reaching tens of millions of users.

In recent months, Ameren reported strong Q4 2025 and full-year earnings growth while successfully issuing US$400 million in senior notes and US$450 million in Ameren Missouri mortgage bonds at fixed interest rates of 4.80% and 5.55%. Together with its ongoing spending on grid upgrades and clean energy, these funding moves emphasize how Ameren is aligning its balance sheet with long-term infrastructure and data center-related power demand. Now we’ll examine how Ameren’s solid earnings and...

Regulatory milestone for lorundrostat Mineralys Therapeutics (MLYS) recently reported that the FDA accepted its New Drug Application for lorundrostat in hypertension, while also updating investors on the Explore OSA trial in obstructive sleep apnea. See our latest analysis for Mineralys Therapeutics. Mineralys Therapeutics’ share price has pulled back over the past quarter, with a 90 day share price return of 19.92% decline and year to date return of 20.72% decline. However, the 1 year total...

The RealReal recently launched its ‘L’ultimo Uomo Reale (I Am Real)’ ad campaign underscoring its authentication promise, reopened its historic Union Square flagship in San Francisco, and continued investing in authentication operations, including hiring a Senior Manager of Inbound Operations in Phoenix. Together, these moves highlight how The RealReal is leaning into physical retail, human expertise, and trust-centric messaging as differentiators in the luxury resale market, while also...

Insider selling and analyst updates put Privia Health Group (PRVA) in focus Privia Health Group (PRVA) is back on investor radar after Chief Financial Officer David Mountcastle sold 5,566 shares, followed by a fresh round of analyst updates after the company’s Q4 earnings release. See our latest analysis for Privia Health Group. At a share price of $22.38, Privia Health Group has seen short term momentum pick up, with a 1 day share price return of 3.66% and a 7 day share price return of...

Artificial intelligence in healthcare is one of the clearest ways technology meets real world need, especially as higher energy prices, geopolitical tension, and sticky inflation keep pressure on costs and productivity. While many sectors face softer activity and rising input prices, AI tools that support better diagnostics, smoother hospital operations, and faster drug discovery speak directly to efficiency and outcomes. This screener focuses on companies applying AI to these problems,...

If you are wondering whether Gen Digital is priced attractively right now, or if the recent volatility is a warning sign, this article focuses squarely on what the current share price might be implying. Over the short term, the stock has recent returns of 1.9% over 7 days, a 15.2% decline over 30 days, a 26.4% decline year to date, a 16.9% decline over 1 year, a 14.9% gain over 3 years, and a 1.2% decline over 5 years. Together, these figures give you a mixed picture of how sentiment has...

Event context and recent performance Lantheus Holdings (LNTH) has drawn fresh attention after its recent trading performance, with the stock up about 3% over the past week, 8% over the past month, and 13% in the past 3 months. See our latest analysis for Lantheus Holdings. At a share price of $78.08, Lantheus has seen short term momentum build with a 30 day share price return of 7.61% and year to date share price return of 16.07%. However, the 1 year total shareholder return of 16.41% and 3...

If you are wondering whether Academy Sports and Outdoors is attractively priced right now, the stock's recent track record and current valuation metrics offer a useful starting point for your own view. The share price closed at US$57.18 recently, with returns of 1.3% over 7 days, a 5.1% decline over 30 days, 9.6% year to date, 69.5% over 1 year, a 11.0% decline over 3 years, and 86.9% over 5 years. This gives you a range of outcomes to weigh. Recent coverage of Academy Sports and Outdoors...

If you are trying to work out whether Credit Acceptance at around US$444 per share looks expensive or offers value, the starting point is understanding what the current share price actually reflects. Over the last week the stock is up 5.0%, while the 1 year return sits at a 5.0% decline and the year to date move is a 2.0% decline, which hints that sentiment around risk and reward has shifted more than once recently. The share price moves sit against a backdrop of ongoing attention on...

Why Virgin Galactic’s latest filings and results are drawing attention Virgin Galactic Holdings (SPCE) has come back into focus after its fourth quarter and full year 2025 results, alongside a new shelf registration for common stock tied to an employee stock ownership plan. The company reported fourth quarter 2025 sales of US$0.312 million and a net loss of US$62.72 million, with full year sales of US$1.54 million and a net loss of US$278.91 million, prompting fresh interest in its capital...

If you are wondering whether WESCO International's share price still offers value, or if the easier gains have already been made, this article breaks down what the current price might be implying. The stock most recently closed at US$278.57, with returns of 1.8% over 7 days, 5.5% over 30 days, 10.5% year to date, 111.4% over 1 year, 110.0% over 3 years, and 232.4% over 5 years. Recent market attention around WESCO International has focused on its role as a key distributor in capital goods...

If you are wondering whether Clearway Energy's share price still offers value after a strong run, the key is understanding what the current market price might already be factoring in. The stock last closed at US$39.64, with returns of 1.2% over 7 days, 12.7% over 30 days, 23.4% year to date, 68.3% over 1 year, 58.3% over 3 years and 94.3% over 5 years. This raises the question of how much of the story is already reflected in the valuation. Recent news around Clearway Energy has focused on...

In its latest results, WillScot Holdings reported a 13% year-over-year decline in EBITDA, a similar drop in units on rent, and wrote off about 15% of its rental fleet, underscoring mounting financial and operational pressure. These fleet impairments and signs of tougher competition, particularly from United Rentals, point to a business mix tilting toward smaller, less profitable segments. Against this backdrop of fleet write-offs and weakening core metrics, we will assess how the news...

Why Brookfield Wealth Solutions is on investors’ radar today Brookfield Wealth Solutions (BNT) has been drawing attention after a period where the share price shows mixed returns across different time frames. This has prompted closer scrutiny of its business mix and current valuation. See our latest analysis for Brookfield Wealth Solutions. The latest 1 day share price return of a 0.4% decline and 90 day share price return of a 12% decline contrast with a 1 year total shareholder return of...

Corteva recently reached a new all-time high, supported by overwhelmingly positive analyst sentiment that now skews toward “Buy” ratings from major firms. Low short interest and strong participation from both Wall Street and individual investors highlight how sentiment alone can materially influence Corteva’s trading activity. We’ll now explore how this wave of bullish analyst support could reshape Corteva’s investment narrative and perceived risk-reward balance. This technology could...

Wondering whether Vera Therapeutics at around US$40.45 is still offering value, or if the easy gains are behind it? This article is designed to help you frame that question clearly. The stock has returned 6.2% over the last week and 3.5% over the last month, while year to date it is down 16.8% but up 102.8% over the past year and a very large amount over three years. This naturally raises questions about what is already priced in. Recent coverage has focused on Vera Therapeutics as investors...

Align Technology (ALGN) is back in focus after a run of analyst upgrades tied to its recent earnings performance, with revenue and net income both showing year over year growth and valuation metrics attracting fresh investor attention. See our latest analysis for Align Technology. At a share price of US$171.87, Align’s recent 7 day share price return of 3.37% and year to date share price return of 10.15% sit against a 1 year total shareholder return of 12.08%, while the 3 year and 5 year...

In late March 2026, Guardant Health announced that its InfinityAI real-world evidence platform was used alongside clinical trial data to support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard therapies. This use of InfinityAI highlights how Guardant’s clinicogenomic data and artificial intelligence can help regulators assess outcomes in genomic subpopulations that are difficult to enroll in...

Some AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders may be a little concerned to see that the Independent Director, John...

Check Point Software Technologies Ltd. ( NASDAQ:CHKP ) just reported some strong earnings, and the market reacted...

If you are wondering whether Louisiana-Pacific at around US$72 a share is offering good value or is already pricing in a lot of expectations, this article will help you frame that question using several valuation lenses. The stock has been choppy recently, with a 2.6% gain over the last 7 days, a 7.2% decline over 30 days, and year-to-date returns showing an 11.7% decline, while the 3-year and 5-year returns sit at 35.5% and 22.4% respectively. Recent attention on Louisiana-Pacific has...

Installed Building Products recently reported fourth-quarter earnings per share of US$3.24, beating expectations while revealing a 9% sales decline in its residential segment and announcing a new US$500 million share repurchase program alongside higher dividends. Management also reduced near-term revenue guidance and cited severe winter weather as a key factor pressuring residential insulation demand, even as commercial activity and acquisition efforts provided a partial offset. Next, we’ll...